Indication

For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of:

  • ≥30 kg/m2 (obesity), or

  • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea [OSA], cardiovascular disease [CVD], prediabetes, or type 2 diabetes mellitus [T2DM])

Medicine details

Medicine name:
tirzepatide (Mounjaro)
SMC ID:
SMC2653
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Endocrine system
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC